

Fanapt® (iloperidone) - New indication

- On April 2, 2024, <u>Vanda Pharmaceuticals announced</u> the FDA approval of <u>Fanapt (iloperidone)</u>, for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
- Fanapt is also approved for the treatment of schizophrenia in adults.
- The approval of Fanapt for the new indication was based on a randomized, double-blind, placebo-controlled study in 392 patients with bipolar I disorder, manic or mixed type. The primary endpoint was change in Young Mania Rating Scale (YMRS) total score from baseline to day 28. The YMRS is an 11-item clinician rated scale traditionally used to assess the degree of manic symptomatology. YMRS total scores may range from 0 to 60 with a higher score reflecting greater severity.
 - The least squares mean change from baseline in YMRS score was -14.0 and -10.0 with Fanapt and placebo, respectively (difference -4.0, 95% CI: -5.70, -2.25).
- Fanapt carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.
- The most common adverse reactions (≥ 5% and 2-fold greater than placebo) with Fanapt use for bipolar mania were tachycardia, dizziness, dry mouth, increased hepatic enzymes, nasal congestion, increased weight, hypotension, and somnolence.
- The recommended dose of Fanapt for acute treatment of manic or mixed episodes associated with bipolar I disorder is 12 mg orally twice daily. The dose should be titrated from 1 mg (see details below).

Titration schedule					Recommended
Day 1	Day 2	Day 3	Day 4	Day 5	dosage
1 mg twice	3 mg twice	6 mg twice	9 mg twice	12 mg twice	12 mg twice
daily	daily	daily	daily	daily	daily

Refer to the Fanapt drug label for dosing for schizophrenia.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.